These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 23934510)
1. Targeting the immune system in the treatment of non-small-cell lung cancer. Rangachari D; Brahmer JR Curr Treat Options Oncol; 2013 Dec; 14(4):580-94. PubMed ID: 23934510 [TBL] [Abstract][Full Text] [Related]
2. The next generation of immunotherapy: keeping lung cancer in check. Somasundaram A; Burns TF J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399 [TBL] [Abstract][Full Text] [Related]
3. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Reck M Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925 [TBL] [Abstract][Full Text] [Related]
4. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? Tanvetyanon T; Gray JE; Antonia SJ Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556 [TBL] [Abstract][Full Text] [Related]
5. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. Chow LQ Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714523 [TBL] [Abstract][Full Text] [Related]
7. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Zielinski C; Knapp S; Mascaux C; Hirsch F Ann Oncol; 2013 May; 24(5):1170-9. PubMed ID: 23393121 [TBL] [Abstract][Full Text] [Related]
8. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer. Lim SW; Ahn MJ Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418 [TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors in lung cancer: past, present and future. Seetharamu N; Budman DR; Sullivan KM Future Oncol; 2016 May; 12(9):1151-63. PubMed ID: 27019997 [TBL] [Abstract][Full Text] [Related]
10. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Langer CJ Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885 [TBL] [Abstract][Full Text] [Related]
11. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. Garon EB Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. Gridelli C; Ascierto PA; Barberis MC; Felip E; Garon EB; O'brien M; Senan S; Casaluce F; Sgambato A; Papadimitrakopoulou V; De Marinis F Expert Opin Biol Ther; 2016 Dec; 16(12):1479-1489. PubMed ID: 27650132 [TBL] [Abstract][Full Text] [Related]
13. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Hayashi H; Nakagawa K Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270 [TBL] [Abstract][Full Text] [Related]
15. New Immunotherapy and Lung Cancer. Sánchez de Cos Escuín J Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733 [TBL] [Abstract][Full Text] [Related]
16. Targeting the immune system to treat lung cancer: rationale and clinical experience. Guibert N; Delaunay M; Mazières J Ther Adv Respir Dis; 2015 Jun; 9(3):105-20. PubMed ID: 25827132 [TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in NSCLC. Johnson DB; Rioth MJ; Horn L Curr Treat Options Oncol; 2014 Dec; 15(4):658-69. PubMed ID: 25096781 [TBL] [Abstract][Full Text] [Related]
18. Nivolumab plus ipilimumab in non-small-cell lung cancer. Reck M; Borghaei H; O'Byrne KJ Future Oncol; 2019 Jul; 15(19):2287-2302. PubMed ID: 31066582 [TBL] [Abstract][Full Text] [Related]
19. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer]. Wang S; Li J Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599 [TBL] [Abstract][Full Text] [Related]
20. [Immune Checkpoint Therapy for Non-Small-Cell Lung Cancer]. Miyauchi E; Inoue A Gan To Kagaku Ryoho; 2016 Jun; 43(6):666-71. PubMed ID: 27306803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]